Comparison

Lixisenatide vs. Retatrutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Lixisenatide

Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.

Retatrutide

Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Lixisenatide	Retatrutide
Germany	Prescription	Unapproved
JP	Prescription	Unapproved
United States	Unapproved	Unapproved

Full entries

Frequently asked questions

What is the difference between Lixisenatide and Retatrutide?: Lixisenatide is classified as "Metabolic", while Retatrutide is classified as "Metabolic". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Lixisenatide or Retatrutide?: The highest available evidence level is "Human RCT" for Lixisenatide and "Human RCT" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Lixisenatide and Retatrutide in Germany and the United States?: Germany: Lixisenatide — Prescription, Retatrutide — Unapproved. United States: Lixisenatide — Unapproved, Retatrutide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Lixisenatide

Retatrutide

Germany

Prescription

Unapproved

Prescription

Unapproved

United States

Unapproved

Frequently asked questions

What is the difference between Lixisenatide and Retatrutide?

Lixisenatide is classified as "Metabolic", while Retatrutide is classified as "Metabolic". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Lixisenatide or Retatrutide?

The highest available evidence level is "Human RCT" for Lixisenatide and "Human RCT" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Lixisenatide and Retatrutide in Germany and the United States?

Germany: Lixisenatide — Prescription, Retatrutide — Unapproved. United States: Lixisenatide — Unapproved, Retatrutide — Unapproved. These are factual summaries with source and review date on the individual pages.